Phase II trial of mFOLFOX6/XELOX plus bevacizumab with oxaliplatin in a stop and go fashion in advanced metastatic colorectal cancer
Phase 2
- Conditions
- advanced colorectal cancer
- Registration Number
- JPRN-UMIN000002042
- Lead Sponsor
- Tohoku Clinical oncology, reserach and Education Society (T-CORE)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 65
Inclusion Criteria
Not provided
Exclusion Criteria
1. patient treated with blood transfusion, blood products or G-CSF within 7 days before registration. 2.patient who has or clinically suspicious for brain metastasis. 3. patient with a mental disorder or a history of a CNS disorder 4. patient with paresthesia 5. patient who need drainage of peritoneal, pleural or pericardial effusion. 6. double cancer 7. hypercalcemia (albumin-modified Ca value 12mg/dl or more). 8. poorly controlled diabetes mellitus. 9. proteinuria (grade 2 or more) 10. history of severe drug hypersensitivity or drug allergy 11. poorly controlled hypertension 12. obvious abnormality in ECG
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method median prpgression free survival (PFS)
- Secondary Outcome Measures
Name Time Method response rate (RR), overall survival (OS), time to treatment failure (TTF), and incidence of neurotoxicity